Clinical studies have shown a protective effect of irisin against metabolic disorders, such as metabolic syndrome and obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, cardiovascular diseases, nonalcoholic fatty liver disease, and metabolic bone diseases [13,14,15,16,17]. Here, FNDC5 is linked to obesity due to melanocortin 4 receptor deficiency.